Pay in 4 interest-free payments of $7.23 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Eli Lilly is conducting a comprehensive Phase III program, with trials studying the drug for obesity and related conditions like knee osteoarthritis
BPC-157: 1
Mounjaro (tirzepatide) uniquely targets both GLP-1 and GIP receptors, potentially offering more substantial weight reduction and improved glycemic control compared to other GLP-1RAs that only target the GLP-1 receptor, such as Ozempic (semaglutide)
P = .4818)
The glucagon receptor stimulation increases energy expenditure and promotes fat breakdown in the liver
US$ 22.65
US$ 20.40
US$ 25.61
US$ 22.11
US$ 24.93
